ストックスクリーナーアプリを入手
2.72
1.50%
0.05
前日終値:
$2.67
開ける：
$2.66
24時間の取引高:
568.16K
Relative Volume:
0.27
時価総額：
$788.63M
収益：
$38.03M
当期純損益:
$-146.40M
株価収益率:
-6.0444
EPS:
-0.45
ネットキャッシュフロー:
$-121.38M
1週間 パフォーマンス:
-1.81%
1か月 パフォーマンス:
-2.17%
6か月 パフォーマンス:
-29.61%
1年 パフォーマンス:
-37.56%
1日の値動き範囲:
$2.61
$2.7289
1週間の範囲:
$2.57
$2.76
52週間の値動き範囲:
$2.335
$6.055
Abcellera Biologics Inc Stock (ABCL) Company Profile
ABCL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ABCL | 2.72 | 788.63M | 38.03M | -146.40M | -121.38M | -0.45 |
| VRTX | 447.47 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.21 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.87 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-02-22 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 再開されました | Piper Sandler | Overweight |
| 2023-02-28 | 開始されました | Cowen | Outperform |
| 2022-12-15 | 開始されました | Goldman | Buy |
| 2022-11-16 | 開始されました | Truist | Buy |
| 2021-12-21 | 開始されました | The Benchmark Company | Buy |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-01-05 | 開始されました | Berenberg | Buy |
| 2021-01-05 | 開始されました | Credit Suisse | Outperform |
| 2021-01-05 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | Stifel | Buy |
すべてを表示
Abcellera Biologics Inc (ABCL) 最新ニュース
ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Bloom Burton Cuts Earnings Estimates for AbCellera Biologics - MarketBeat
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 - Business Wire
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings - MarketBeat
AbCellera Unveils Breakthrough T-Cell Platform Data, Shows Promise in Cancer Treatment | ABCL Stock News - StockTitan
AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at Benchmark - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Given "Buy" Rating at Stifel Nicolaus - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
AbCellera stock price target cut, keeps Outperform on strategic pivot By Investing.com - Investing.com UK
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Earnings call: AbCellera reports steady Q3 2024 revenue amidst R&D growth - Investing.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Developments - GuruFocus.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
AbCellera Reports Q3 2024 Business Results - The Globe and Mail
AbCellera Biologics Reports Q3 2024 Financial Results - TipRanks
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript - Nasdaq
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Abcellera Biologics earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
AbCellera Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
Laureate Education Inc (LAUR-Q) QuotePress Release - The Globe and Mail
AbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To K - GuruFocus.com
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
AbCellera Biologics (ABCL) Set to Announce Quarterly Earnings on Monday - MarketBeat
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
AbCellera to Present at Upcoming Investor Conferences in November 2024 - Business Wire
3 Promising Penny Stocks On US Exchanges With Over $600M Market Cap - Yahoo Finance
Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5%Here's What Happened - MarketBeat
AbCellera: A Platform To Pipeline Transition - Seeking Alpha
AbCellera Biologics (NASDAQ:ABCL) Trading Up 5.2%Here's What Happened - MarketBeat
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 - Lucknow Sentinel
Dark Forest Capital Management LP Buys 45,721 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Acquired by Renaissance Technologies LLC - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Average Price Target from Analysts - MarketBeat
Wall Street SWOT: AbCellera stockBiotech firm's platform shows promise amid challenges - Investing.com
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - BioSpace
Abcellera Biologics Inc (ABCL) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):